Grifols (GIKLY) Long-Term Investments (2010 - 2025)
Grifols (GIKLY) reported Long-Term Investments of $112.9 million for Q4 2025, up 53.14% on a YoY basis from $73.7 million in Q4 2024, and up 53.14% quarter-over-quarter from $73.7 million in Q4 2024.
Grifols (GIKLY) Long-Term Investments (2010 - 2025) Analysis & Trends
Grifols has reported Long-Term Investments for 16 years, with the latest figure at $112.9 million in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Investments rose 53.14% year-over-year to $112.9 million; the trailing twelve-month figure through Dec 2025 stood at $112.9 million (up 53.14% YoY), and the FY2025 full-year result was $112.9 million, up 1781.87% from the prior year.
- Long-Term Investments for Q4 2025 stood at $112.9 million, up from $73.7 million in the prior quarter.
- The five-year high for Long-Term Investments was $1.8 billion in Q4 2021, with the low at $73.7 million in Q4 2024.
- Historically, Long-Term Investments has averaged $786.5 million across 5 years, with a median of $453.0 million in 2023.
- Annual changes were most pronounced in 2021 — Long-Term Investments soared 423.86% — and 2024, when it tumbled 83.72%.
- Grifols' Long-Term Investments stood at $1.8 billion in 2021, then retreated by 13.39% to $1.5 billion in 2022, then slumped by 70.36% to $453.0 million in 2023, then plunged by 83.72% to $73.7 million in 2024, then soared by 53.14% to $112.9 million in 2025.
- The last three Long-Term Investments figures came in at $112.9 million (Q4 2025), $73.7 million (Q4 2024), and $453.0 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 133.47 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 3.12 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 268.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 983.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 1.63 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 366.00 Mn |
| 10 | Grifols | - | - | - | 112.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 112.91 Mn |
| Dec 31, 2024 | 73.73 Mn |
| Dec 31, 2023 | 452.97 Mn |
| Dec 31, 2022 | 1.53 Bn |
| Dec 31, 2021 | 1.76 Bn |
| Dec 31, 2020 | -544.88 Mn |
| Sep 30, 2020 | 194.29 Mn |
| Mar 31, 2020 | 504.50 Mn |
| Dec 31, 2019 | 126.71 Mn |
| Sep 30, 2019 | 156.09 Mn |
| Mar 31, 2019 | 147.46 Mn |
| Dec 31, 2018 | 258.99 Mn |
| Sep 30, 2018 | 15.48 Mn |
| Jun 30, 2018 | 269.46 Mn |
| Mar 31, 2018 | 134.15 Mn |
| Dec 31, 2017 | 257.87 Mn |
| Jun 30, 2017 | 245.73 Mn |
| Dec 31, 2016 | 4.05 Mn |
| Sep 30, 2016 | 100.76 Mn |
| Jun 30, 2016 | 98.35 Mn |